New hope for rare, aggressive cancer: drug cocktail shows promise in trial
NCT ID NCT02820857
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether adding the drug bevacizumab (Avastin) to standard chemotherapy (Folfiri) helps people with advanced, aggressive neuroendocrine carcinoma live longer after their first treatment stops working. The trial included 153 adults with inoperable cancer that started in the digestive tract or an unknown location. The main goal was to see how many patients were alive six months after starting the new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bevacizumab (Avastin) plus Folfiri (a chemotherapy combination)
- What this could lead to
- If successful, this could provide a new second-line treatment option for patients with advanced neuroendocrine carcinoma, potentially extending survival.
- What could go wrong
- This is a Phase 2 trial with a modest sample size, so results may not be definitive. The combination may not improve survival over Folfiri alone and could cause side effects like bleeding or high blood pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE CARCINOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Département d'Oncologie Médicale, Hôpital Saint-Antoine
Paris, 75012, France
-
Département d'Oncologie Médicale, Institut Paoli Calmettes
Marseille, 13009, France
-
Département de Cancérologie Urologique et Digestive, Centre Oscar Lambret
Lille, 59020, France
-
Département de cancérologie médicale - Groupe des tumeurs endocrines, Centre Léon Bérard
Lyon, 69008, France
-
Pôle Régional de Cancérologie, CHU de Poitiers
Poitiers, 86021, France
-
Service d'Hépato-Gastroenterologie et Oncologie Digestive, Hôpital Européen Georges Pompidou, APHP
Paris, 75015, France
-
Service d'Hépato-Gastroenterologie et Oncologie Digestive, Hôpital Sud, CHU d'Amiens
Amiens, 80054, France
-
Service d'Hépato-Gastroentérologie et Cancérologie, Hôpital Robert Debré, CHU de Reims
Reims, 51100, France
-
Service d'Hépato-Gastroentérologie et Oncologie Digestive, CHU de Dijon
Dijon, 21000, France
-
Service d'Hépato-Gastroentérologie et d'Oncologie Digestive, Hôpital Haut Lévêque, CHU Bordeaux
Pessac, 33604, France
-
Service d'Hépato-Gastroentérologie et d'Oncologie Digestive, Hôpital de la Timone, APHM
Marseille, 13365, France
-
Service d'Hépatogastroentéologie, Hôpital Michallon, CHU de Grenoble
Grenoble, 38043, France
-
Service d'Hépatogastroentérologie, CHR d'Orléans
Orléans, 45067, France
-
Service d'Hépatogastroentérologie, CHU d'Angers
Angers, 49933, France
-
Service d'Hépatogastroentérologie, Hôpital Pontchaillou, CHU de Rennes
Rennes, 35000, France
-
Service d'Oncologie Endocrinienne, Institut Gustave Roussy
Villejuif, 94805, France
-
Service d'Oncologie Médicale - Hôpital Edouard Herriot - Hospices Civils de Lyon
Lyon, 69437, France
-
Service d'Oncologie Médicale, Hôpital Civil, CHU de Strasbourg
Strasbourg, 67200, France
-
Service d'Oncologie Médicale, Hôpital Saint Eloi, CHU de Montpellier
Montpellier, 34298, France
-
Service d'Oncologie et Radiothérapie, Institut Sainte Catherine
Avignon, 84918, France
-
Service de Gastro-Entérologie, Hôpital Nord, CHU de ST-Etienne
Saint-Priest-en-Jarez, 42270, France
-
Service de Gastroentérologie et Oncologie Digestive, Hôpital Avicenne
Bobigny, 93000, France
-
Service de Gastroentérologie et Pancréatologie, Hôpital Beaujon, APHP
Clichy, 92118, France
-
Service de Gastroentérologie, CHU Henri Mondor
Créteil, 94000, France
-
Service de Gastroentérologie, CHU de Rouen
Rouen, 76031, France
-
Service de Gastroentérologie, Hôpital Cochin, APHP
Paris, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug targets Hard-to-Treat neuroendocrine cancers
- New hope for rare cancers: experimental drug ADCT-701 enters human trials
- New study maps cancer treatment journeys across latin america
- New drug combo targets Hard-to-Treat lung cancer in early trial
- New drug XmAb20717 tested in rare cancers – trial suspended